Clinical trials in testicular cancer

Lead Research Organisation: MRC Clinical Trials Unit

Abstract

Testicular cancer is the most common cancer in young men. If diagnosed at an early stage, the great majority of patients will be cured. Even those with very advanced disease have a relatively high chance of cure, however this may require them to undergo intensive and toxic treatment, and they will potentially live a long time with any adverse effects of otherwise successful treatment. The MRC CTUs research in patients with testicular cancer has two main aims; to improve the cure rates of those with the poorest prognosis disease and to maintain cure rates while reducing the short and long term side effects of treatment in those with a good prognosis. This is done through the conduct of clinical trials, often involving international partners to ensure the trials are large enough to provide definitive answers. These can then guide the treatment of future patients.

Technical Summary

Testicular cancer is relatively rare - c1900 new cases per annum in the UK - but is the most common malignancy in young men, and one which has doubled in incidence in the UK over the last 30 years. Diagnosed early, the chances of cure are now excellent, but the age of the typical patient means testicular cancer rates highly in terms of potential years of life lost while surviving patients will live a long time with the side effects of successful treatment. Goals for MRC CTU research into this area are therefore (a) in the poorer prognosis patients, improving survival rates, (b) in the good prognosis patients, minimising the impact of treatment on working status, fertility and general health in the short and long term - without compromising the high cure rates. In December 2009 we successfully completed accrual to the first randomised trial of a novel chemotherapy regimen (CBOP/BEP) for poor prognosis metastatic germ cell tumours. The results will be available in 2010 and will inform decisions on an international strategy for these patients. Updated results of two trials will inform the management of patients with stage I disease. In seminoma, the TE19 trial (in press, Journal of Clinical Oncology) showed that a single dose of carboplatin achieved clinically equivalent results to 2-3 weeks of radiotherapy in terms of relapse-free survival, and reduced the incidence of contralateral testis tumours. In non-seminoma, low risk patients are typically managed by post-operative surveillance, but the optimal surveillance schedule is unknown. The TE08 trial randomised patients between two different radiological surveillance schedules and updated results confirmed that stage at relapse was not compromised by carrying out less frequent CTs (presented at the NCRI conference, October 2009). Surveillance is of increasing interest in stage I seminoma patients, 80% of whom will be cured by surgery alone. However, there is a requirement to balance the need for effective post-operative monitoring to enable prompt detection of relapse with minimising excessive exposure to ionising radiation from current scanning modalities. Current surveillance schedules are based around frequent CT scanning, which has a non-ignorable level of radiation and associated cancer risk. This could be minimised by a reduction in CT scans frequency or by a switch from CT to MRI which uses no radiation. Our randomised phase III trial (TRISST) opened in 2008 and will establish whether a reduced imaging schedule or MRI could be used as a safe and effective alternative to standard CT-based surveillance.

Publications

10 25 50

publication icon
Gilbert DC (2016) Defining a New Prognostic Index for Stage I Nonseminomatous Germ Cell Tumors Using CXCL12 Expression and Proportion of Embryonal Carcinoma. in Clinical cancer research : an official journal of the American Association for Cancer Research

 
Description Testis - ASCO 50 years review
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical reviews
Impact A review article, published in the leading international oncology journal (Journal of Clinical Oncology), reflecting on the last 50 years of research into testicular cancer therapies, cites the contribution of two of the MRC trials to advances in this area and subsequent improvements in cure rates and survival.
URL http://jco.ascopubs.org/content/32/28/3085.long
 
Guideline Title Guidelines on Testicular Cancer
Description Testis EAU guidelines
Geographic Reach Europe 
Policy Influence Type Citation in clinical guidelines
Impact MRC Testicular cancer trials referenced throughout, informing management of all stages of disease
 
Guideline Title European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the EGCCCG
Description Testis EGCCCG guidelines
Geographic Reach Europe 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title ESMO Clinical Recommendations for the diagnosis, treatment and follow-up of testicular seminoma and non-seminoma
Description Testis ESMO guidelines
Geographic Reach Europe 
Policy Influence Type Citation in clinical guidelines
URL http://www.esmo.org/Guidelines/Genitourinary-Cancers/Testicular-Seminoma-and-Non-Seminoma
 
Guideline Title NCCN Clinical Practice Guidelines in Oncology: Testicular Cancer
Description Testis NCCN guidelines
Geographic Reach North America 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Management of adult testicular germ cell tumours
Description Testis SIGN guidelines
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
URL http://www.sign.ac.uk/guidelines/fulltext/124/index.html
 
Description CRUK Clinical Trial Award (TRISST trial TE24)
Amount £767,448 (GBP)
Funding ID CRUK/07/020 
Organisation Cancer Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 10/2007 
End 09/2016
 
Title TE08 trial database 
Description Data collected specifically to allow monitoring and analysis of the primary research questions addressed by the TE08 trial. The database also includes data relevant not only to the primary question, but which provides a unique resource with which to address related questions. External groups may request access to the data through the independent Trial Steering Committee 
Type Of Material Improvements to research infrastructure 
Year Produced 2007 
Provided To Others? Yes  
Impact Monitoring and analysis of the trial and dissemination of the results 
 
Title TE08/22 Sample Collection 
Description Tissue samples from patients in the MRC stage I non-seminoma studies TE08 and TE22; collected specifically for investigation of potential molecular markers of prognosis. 
Type Of Material Biological samples 
Provided To Others? No  
Impact First analyses completed and presented at NCRI conference November 2012; identified an independent prognostic marker that mayhelp with risk stratification and tailoring of adjuvant therapy for stage I nonseminoma. 
 
Title TE19 trial database 
Description Data collected specifically to allow monitoring and analysis of the primary research questions addressed by the TE19 trial. The database also includes data relevant not only to the primary question, but which provides a unique resource with which to address related questions. External groups may request access to the data through the independent Trial Steering Committee 
Type Of Material Improvements to research infrastructure 
Provided To Others? Yes  
Impact Monitoring and analysis of the trial, dissemination of the results 
 
Title TE22 trial database 
Description Data collected specifically to allow monitoring and analysis of the primary research questions addressed by the TE22 trial. The database also includes data relevant not only to the primary question, but which provides a unique resource with which to address related questions. External groups may request access to the data through the independent Trial Steering Committee 
Type Of Material Improvements to research infrastructure 
Year Produced 2007 
Provided To Others? Yes  
Impact Monitoring and analysis of the trial and dissemination of the results 
 
Title TE23 sample collection 
Description Repositry of tumour and blood samples from participants in the TE23 trial. 
Type Of Material Biological samples 
Year Produced 2016 
Provided To Others? Yes  
Impact Other research groups are able to gain access to the samples through application to the Trial Steering Committee. To date, samples have been shared with a research group at Cambridge University who will use the samples to investigate diagnostic and prognostic blood-based microRNA markers, and other short non-coding RNA profiles, in testicular germ cell tumours. 
 
Title TE23 trial database 
Description Data collected specifically to allow monitoring and analysis of the primary research questions addressed by the TE23 trial. The database also includes data relevant not only to the primary question, but which provides a unique resource with which to address related questions. External groups may request access to the data through the independent Trial Steering Committee 
Type Of Material Improvements to research infrastructure 
Year Produced 2015 
Provided To Others? Yes  
Impact Final analysis took place in November 2010 and results were presented nationally and internationally in 2011. 
 
Title TRISST clinical trial database 
Description Data collected specifically to allow monitoring and analysis of the primary research questions addressed by the TRISST trial. The database also includes data relevant not only to the primary question, but which provides a unique resource with which to address related questions. External groups may request access to the data through the independent Trial Steering Committee 
Type Of Material Improvements to research infrastructure 
Provided To Others? No  
Impact Trial is ongoing. The database is currently used for ongoing data collection, checking and monitoring. 
 
Description Biomarkers to predict relapse in Stage I NSTGCT 
Organisation Institute of Cancer Research UK
Country United Kingdom 
Sector Academic/University 
PI Contribution The genetic marker data generated will be analysed by the CTU and integrated with the clinical trial data (treatment and follow-up) held by the CTU. The work will investigate potential biomarkers for relapse in patients with stage I non-seminoma testicular germ cell tumour and whether they may contribute overall to better risk stratification to help with treatment decisions. We will jointly present and publish this work.
Collaborator Contribution The NCRI Testis Tumour CSG as a group endorses this translation work and encourages national collaboration. The team at the ICR will retrospectively collect samples held by centres collaborating in closed testicular cancer trials (MRC TE08 and TE22) conducted by the CTU. This will allow the development of a tissue resource of well-characterised formalin fixed paraffin embedded (FFPE) material for a planned investigation of markers for relapse in stage I non-seminoma and for future ethically approved studies.
Impact Publication in Clinical Cancer Research (2016). This is a multidisciplinary collaboration comprising clinical laboratory scientists, oncologists and CTU statisticians and trial managers.
Start Year 2008
 
Description Biomarkers to predict relapse in Stage I NSTGCT 
Organisation National Cancer Research Institute (NCRI)
Department NCRI Testis Tumour CSG
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution The genetic marker data generated will be analysed by the CTU and integrated with the clinical trial data (treatment and follow-up) held by the CTU. The work will investigate potential biomarkers for relapse in patients with stage I non-seminoma testicular germ cell tumour and whether they may contribute overall to better risk stratification to help with treatment decisions. We will jointly present and publish this work.
Collaborator Contribution The NCRI Testis Tumour CSG as a group endorses this translation work and encourages national collaboration. The team at the ICR will retrospectively collect samples held by centres collaborating in closed testicular cancer trials (MRC TE08 and TE22) conducted by the CTU. This will allow the development of a tissue resource of well-characterised formalin fixed paraffin embedded (FFPE) material for a planned investigation of markers for relapse in stage I non-seminoma and for future ethically approved studies.
Impact Publication in Clinical Cancer Research (2016). This is a multidisciplinary collaboration comprising clinical laboratory scientists, oncologists and CTU statisticians and trial managers.
Start Year 2008
 
Description TE08 trial 
Organisation National Cancer Research Institute (NCRI)
Department NCRI Testis Tumour CSG
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution Design, coordination and analysis of the trial, and dissemination of the results
Collaborator Contribution This collaboration includes all the staff at each of the clinical sites that have participated in the TE08 clinical trial. Each site identified patients potentially suitable for the trial, sought informed consent, treated and followed up patients within the trial and provided data through completion and return of case record forms.The NCRN provides the infrastructure in which the trial was run at participating hospitals. In particular, it supports local research nurses and data managers who are responsible for collecting and returning trial data to the CTU.The NCRI Brain Tumour CSG as a group endorses the TE08 trial and encourages national collaboration
Impact The collaboration enabled the TE08 trial to complete recruitment and collect follow-up data. The results have been published in the Journal of Clinical Oncology (Rustin et al, JCO, 2007). Updated results were presented in poster form at the NCRI conference in 2009. This is a multidisciplinary collaboration, comprising clinicians and research nurses in the collaborating centres, and CTU statisticians and trial managers.
 
Description TE08 trial 
Organisation National Cancer Research Institute (NCRI)
Department National Cancer Research Network (NCRN)
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution Design, coordination and analysis of the trial, and dissemination of the results
Collaborator Contribution This collaboration includes all the staff at each of the clinical sites that have participated in the TE08 clinical trial. Each site identified patients potentially suitable for the trial, sought informed consent, treated and followed up patients within the trial and provided data through completion and return of case record forms.The NCRN provides the infrastructure in which the trial was run at participating hospitals. In particular, it supports local research nurses and data managers who are responsible for collecting and returning trial data to the CTU.The NCRI Brain Tumour CSG as a group endorses the TE08 trial and encourages national collaboration
Impact The collaboration enabled the TE08 trial to complete recruitment and collect follow-up data. The results have been published in the Journal of Clinical Oncology (Rustin et al, JCO, 2007). Updated results were presented in poster form at the NCRI conference in 2009. This is a multidisciplinary collaboration, comprising clinicians and research nurses in the collaborating centres, and CTU statisticians and trial managers.
 
Description TE19 trial 
Organisation European Organisation for Research and Treatment of Cancer (EORTC)
Country European Union (EU) 
Sector Charity/Non Profit 
PI Contribution Design, coordination and analysis of the trial, and dissemination of the results
Collaborator Contribution This collaboration includes all the staff at each of the clinical sites that have participated in the TE19 clinical trial. Each site identified patients potentially suitable for the trial, sought informed consent, treated and followed up patients within the trial and provided data through completion and return of case record forms.The NCRN provides the infrastructure in which the trial was run at participating hospitals. In particular, it supports local research nurses and data managers who are responsible for collecting and returning trial data to the CTU.The NCRI Testis Tumour CSG as a group endorses the TE19 trial and encourages national collaborationTE19 was a collaborative trial with the EORTC; they coordinated participation of several European countries in the trial.
Impact The collaboration enabled the TE19 trial to continue to collect long-term follow-up data and results from this mature data were presented at a plenary presentation at the American Society for Clinical Oncology in 2008. The long-term results were published in the Journal of Clinical Oncology in 2011. This is a multidisciplinary collaboration, comprising clinicians and research nurses in the collaborating centres, and CTU statisticians and trial managers.
 
Description TE19 trial 
Organisation National Cancer Research Institute (NCRI)
Department NCRI Testis Tumour CSG
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution Design, coordination and analysis of the trial, and dissemination of the results
Collaborator Contribution This collaboration includes all the staff at each of the clinical sites that have participated in the TE19 clinical trial. Each site identified patients potentially suitable for the trial, sought informed consent, treated and followed up patients within the trial and provided data through completion and return of case record forms.The NCRN provides the infrastructure in which the trial was run at participating hospitals. In particular, it supports local research nurses and data managers who are responsible for collecting and returning trial data to the CTU.The NCRI Testis Tumour CSG as a group endorses the TE19 trial and encourages national collaborationTE19 was a collaborative trial with the EORTC; they coordinated participation of several European countries in the trial.
Impact The collaboration enabled the TE19 trial to continue to collect long-term follow-up data and results from this mature data were presented at a plenary presentation at the American Society for Clinical Oncology in 2008. The long-term results were published in the Journal of Clinical Oncology in 2011. This is a multidisciplinary collaboration, comprising clinicians and research nurses in the collaborating centres, and CTU statisticians and trial managers.
 
Description TE19 trial 
Organisation National Cancer Research Institute (NCRI)
Department National Cancer Research Network (NCRN)
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution Design, coordination and analysis of the trial, and dissemination of the results
Collaborator Contribution This collaboration includes all the staff at each of the clinical sites that have participated in the TE19 clinical trial. Each site identified patients potentially suitable for the trial, sought informed consent, treated and followed up patients within the trial and provided data through completion and return of case record forms.The NCRN provides the infrastructure in which the trial was run at participating hospitals. In particular, it supports local research nurses and data managers who are responsible for collecting and returning trial data to the CTU.The NCRI Testis Tumour CSG as a group endorses the TE19 trial and encourages national collaborationTE19 was a collaborative trial with the EORTC; they coordinated participation of several European countries in the trial.
Impact The collaboration enabled the TE19 trial to continue to collect long-term follow-up data and results from this mature data were presented at a plenary presentation at the American Society for Clinical Oncology in 2008. The long-term results were published in the Journal of Clinical Oncology in 2011. This is a multidisciplinary collaboration, comprising clinicians and research nurses in the collaborating centres, and CTU statisticians and trial managers.
 
Description TE22 trial 
Organisation National Cancer Research Institute (NCRI)
Department NCRI Testis Tumour CSG
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution Design, coordination and analysis of the trial, and dissemination of the results.
Collaborator Contribution This collaboration includes all the staff at each of the clinical sites that have participated in the TE22 clinical trial. Each site identified patients potentially suitable for the trial, sought informed consent, treated and followed up patients within the trial and provided data through completion and return of case record forms.The NCRN provides the infrastructure in which the trial was run at participating hospitals. In particular, it supports local research nurses and data managers who are responsible for collecting and returning trial data to the CTU.The NCRI Brain Tumour CSG as a group endorses the TE22 trial and encourages national collaboration.
Impact The collaboration enabled the TE22 trial to complete the trial and collect follow-up data. The results have been published in the Journal of Clinical Oncology (Huddart et al, JCO, 2007). This was a multidisciplinary collaboration involving oncologists and research staff at participating sites, central review radiologists and statistical and trial management staff at the MRC CTU
 
Description TE22 trial 
Organisation National Cancer Research Institute (NCRI)
Department National Cancer Research Network (NCRN)
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution Design, coordination and analysis of the trial, and dissemination of the results.
Collaborator Contribution This collaboration includes all the staff at each of the clinical sites that have participated in the TE22 clinical trial. Each site identified patients potentially suitable for the trial, sought informed consent, treated and followed up patients within the trial and provided data through completion and return of case record forms.The NCRN provides the infrastructure in which the trial was run at participating hospitals. In particular, it supports local research nurses and data managers who are responsible for collecting and returning trial data to the CTU.The NCRI Brain Tumour CSG as a group endorses the TE22 trial and encourages national collaboration.
Impact The collaboration enabled the TE22 trial to complete the trial and collect follow-up data. The results have been published in the Journal of Clinical Oncology (Huddart et al, JCO, 2007). This was a multidisciplinary collaboration involving oncologists and research staff at participating sites, central review radiologists and statistical and trial management staff at the MRC CTU
 
Description TE23 data and sample sharing - University of Cambridge 
Organisation University of Cambridge
Department Department of Pathology
Country United Kingdom 
Sector Academic/University 
PI Contribution Provision of biological samples and data collected within the TE23 clinical trial in testicular cancer
Collaborator Contribution Undertaking a project utilising the data and samples from the TE23 clinical trial
Impact None
Start Year 2016
 
Description TE23 trial 
Organisation Institute of Cancer Research UK
Country United Kingdom 
Sector Academic/University 
PI Contribution Trial design, coordination and analysis
Collaborator Contribution The NCRI testicular cancer clinical studies group supported the trial and helped promote collaboration. The participating sites were responsible for the identification, consent and entry of patients into the TE23 trial, administration of treatment, and provision of patient data. The NCRN provides infrastructure funding to support clinical trials. Laboratory scientists at the ICR supported tumour and blood sample collection during the trial.
Impact Completion of the trial; publication in European Urology (2015). This is a multidisciplinary collaboration, comprising clinicians and research nurses in the collaborating centres, and CTU statisticians and trial managers.
 
Description TE23 trial 
Organisation National Cancer Research Institute (NCRI)
Department NCRI Testis Tumour CSG
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution Trial design, coordination and analysis
Collaborator Contribution The NCRI testicular cancer clinical studies group supported the trial and helped promote collaboration. The participating sites were responsible for the identification, consent and entry of patients into the TE23 trial, administration of treatment, and provision of patient data. The NCRN provides infrastructure funding to support clinical trials. Laboratory scientists at the ICR supported tumour and blood sample collection during the trial.
Impact Completion of the trial; publication in European Urology (2015). This is a multidisciplinary collaboration, comprising clinicians and research nurses in the collaborating centres, and CTU statisticians and trial managers.
 
Description TE23 trial 
Organisation National Cancer Research Institute (NCRI)
Department National Cancer Research Network (NCRN)
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution Trial design, coordination and analysis
Collaborator Contribution The NCRI testicular cancer clinical studies group supported the trial and helped promote collaboration. The participating sites were responsible for the identification, consent and entry of patients into the TE23 trial, administration of treatment, and provision of patient data. The NCRN provides infrastructure funding to support clinical trials. Laboratory scientists at the ICR supported tumour and blood sample collection during the trial.
Impact Completion of the trial; publication in European Urology (2015). This is a multidisciplinary collaboration, comprising clinicians and research nurses in the collaborating centres, and CTU statisticians and trial managers.
 
Description TRISST trial 
Organisation National Cancer Research Institute (NCRI)
Department NCRI Testis Tumour CSG
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution Trial design, coordination and analysis
Collaborator Contribution This trial is a collaboration with the NCRN which provides infrastructure support for conducting studies across the UK. The participating sites are responsible for the identification, consent and entry of patients into the trial, administration of trial procedures and provision of patient data. The NCRI Testis Cancer CSG has helped support the set up of the trial and helps promote collaboration and participation.
Impact Ongoing. This is a multi-disciplinary collaboration including clinicians and research nurses at participating sites, as well as statisticians and trial/data management staff at the trials unit.
Start Year 2008
 
Description TRISST trial 
Organisation National Cancer Research Institute (NCRI)
Department National Cancer Research Network (NCRN)
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution Trial design, coordination and analysis
Collaborator Contribution This trial is a collaboration with the NCRN which provides infrastructure support for conducting studies across the UK. The participating sites are responsible for the identification, consent and entry of patients into the trial, administration of trial procedures and provision of patient data. The NCRI Testis Cancer CSG has helped support the set up of the trial and helps promote collaboration and participation.
Impact Ongoing. This is a multi-disciplinary collaboration including clinicians and research nurses at participating sites, as well as statisticians and trial/data management staff at the trials unit.
Start Year 2008
 
Description Teenage and young adult (MAGIC consortium) 
Organisation Dana-Farber Cancer Institute
Department Department of Medical Oncology
Country United States 
Sector Academic/University 
PI Contribution Provision of data on teenagers and young adults from the MRC testicular cancer trials (TE09, TE13, TE20) in adults to a collaborative study investigating evidence to support or not the different prognostic classifications and treatment approaches used in younger and older testicular cancer patients.
Collaborator Contribution Compilation of the combined data base including data from the US COG studies; analysis of the combined data
Impact Establishment of a multidisciplinary (clinicians and statisticians) US/European collaborative group; establishment of a database in which patients within the same age range, treated on paediatric and adult protocols, are combined and the different management approaches taken can be compared with respect to patient outcomes.
Start Year 2011
 
Title TE19 carboplatin 
Description Carboplatin is a well established cancer drug, but its use as a single dose treatment for early stage testicular seminoma, as an alternative to 2-3 weeks of daily radiotherapy was first evaluated in the MRC-funded TE19 randomised trial. Initial results were published in 2005 and longer term results, first published in 2010, confirmed non-inferiority with respect to risk of relapse and a significantly reduced rate of contralateral testicular cancers. 
Type Therapeutic Intervention - Drug
Current Stage Of Development Wide-scale adoption
Year Development Stage Completed 2010
Development Status Closed
Clinical Trial? Yes
Impact It is now a standard management option offering a single one-off outpatient treatment and more rapid return to work compared with the previous standard (radiotherapy); widely cited in international guidance documents with subsequent uptake confirmed by several national and international surveys. 
URL http://www.controlled-trials.com/ISRCTN27163214/
 
Title TE23 results 
Description The CBOP/BEP chemotherapy combination was evaluated within the TE23 trial (funded by CR UK); this randomised phase II trial met its primary outcome showing the required level of activity to support a phase III trial. This is a rare disease and a phase III trial would require international collaboration; discussions are ongoing. 
Type Therapeutic Intervention - Drug
Current Stage Of Development Late clinical evaluation
Year Development Stage Completed 2011
Development Status Closed
Clinical Trial? Yes
Impact The trial showed that the CBOP/BEP combination has the potential to improve outcomes of patients with the most advanced forms of testicular cancer and has led to ongoing discussions around a definitive phase III trial. 
URL http://public.ukcrn.org.uk/Search/StudyDetail.aspx?StudyID=1420
 
Title TRISST (TE24) 
Description Surveillance is an increasingly widely used management option for patients with stage I testicular seminoma, but requires regular radiological surveillance in order to detect recurrences early. CT scans are most widely used, but frequency varies considerably, and radiation associated with their use is a serious concern in this young, good prognosis population. The TRISST trial is factorial non-inferiority trial looking at 2 ways of potentially reducing radiation associated with surveillance scanning: a reduced scan frequency and/or replacement of CT scans with MRI scans. The trial is currently open to recruitment, due to complete in 2014, and is funded by CR UK 
Type Diagnostic Tool - Imaging
Current Stage Of Development Late clinical evaluation
Year Development Stage Completed 2008
Development Status Under active development/distribution
Clinical Trial? Yes
Impact None as yet - this is the only randomised trial addressing these questions. 
 
Description SDF1 study GU ASCO presentation 2013 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Prompted addition of further data to the translational study and re-analysis

Carried out further analyses which added to original conclusions
Year(s) Of Engagement Activity 2013
URL http://meetinglibrary.asco.org/content/107239-134
 
Description TE19 press release 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Media (as a channel to the public)
Results and Impact Press release summarising results of the TE19 trial disseminated to coincide with conference presentation

n/a
Year(s) Of Engagement Activity 2008
 
Description TE23 ASCO presentation 2011 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Sparked debate about next trial in this setting

Shared information on new trial results and prompted debate around collaboration for future trials
Year(s) Of Engagement Activity 2011
URL http://meetinglibrary.asco.org/content/81624-102
 
Description TE23 summary for Cancer Research UK website 
Form Of Engagement Activity Engagement focused website, blog or social media channel
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact A plain English summary of the results from the TE23 trial was published on the Cancer Research UK website (aimed at patients and the general public).
Year(s) Of Engagement Activity 2015
URL http://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-looking-at-chemotherapy-f...